Ancora.ai’s 2nd Edition Impact Report Released: A Digital Tool Continues to Improve Clinical Trial Access

Nov. 21, 2024

At Ancora.ai, we recognize the need for an easier way to find clinical trials. Currently, only 3–5% of cancer patients participate in clinical trials and being invited to a trial today is largely based on luck

We have experienced firsthand the challenges many patients face including the lack of awareness of trials and the difficulty of finding relevant trials. We believe that everyone should be able to access clinical research, and that technology can help unlock access to trials for the broader population.

We are proud to be releasing the second edition of our Ancora.ai Impact Report. To evaluate our progress on our mission, we analyzed one year of data to understand who we were able to reach with our digital tool and how we were able to support them in accessing trials. Additionally we highlighted our radiopharmaceutical trial finder release and our recent article with Tufts CSDD in Global DIA Forum analyzing challenges patients face today when being referred to a clinical trial.

Link to Global Radiopharmaceutical Trial Finder Tool
Link to DIA Global Forum Article with Tufts CSDD

We would like to thank all the patients, families and healthcare practitioners who have used Ancora.ai and supported our mission. We’d also like to thank our partners and sponsors who have been instrumental in expanding our reach and impact.

To our readers, we hope you enjoy our impact report and we strongly encourage anyone who is interested to join us on the journey to make clinical trials more accessible to reach out.

For a deeper look into the survey’s findings, read the full report.

Thank you to our partners for helping amplify our work:

Thank you to our sponsors for supporting our work: